19 completed, 2 unknown, 1 withdrawn. 10 Phase 3, 6 Phase 4, 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 10 |
| Phase 4 | 6 | Completed 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 2 | Completed 2 |
Follow Synflorix: new trials by email Literature Review of Synflorix trials Research Report on Synflorix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults. 10 or 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine - Pneumococcal Vaccine Adverse Reaction | Unknown | Sungkyunkwan University | 1000000 | 2021-08-01 | 2020-09-16 | |
| Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children PCV10, PCV13 - Pneumonia, Meningitis | Completed | University of Witwatersrand, South Africa | 600 | 2020-02-14 | 2024-08-23 | |
| Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants Pneumosil, Prevenar 13, Synflorix - Pneumonia, Pneumococcal | Phase 3 | Completed | PATH | 660 | 2019-07-18 | 2022-04-20 |
| Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 201 | 2019-04-08 | 2022-07-27 |
| Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants Pneumosil, Synflorix - Pneumonia, Pneumococcal | Phase 3 | Completed | PATH | 2250 | 2017-06-21 | 2020-07-14 |
| Evaluation of PCV Schedules in a Naive Population in Vietnam PCV 2p+1, PCV 3p+0, PCV 1p+1 - Pneumonia, Pneumococcal | Phase 4 | Completed | Nagasaki University | 18652 | 2016-10-01 | 2024-04-19 |
| PCV10 Immunogenicity Study Nepal 2015 10-valent pneumococcal conjugate vaccine - Streptococcus Pneumoniae | Phase 4 | Completed | University of Oxford | 304 | 2015-08-21 | 2018-01-11 |
| Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers PATH-wSP, Synflorix, Pentavac - Pneumonia, Pneumococcal | Phase 1 / Phase 2 | Completed | PATH | 304 | 2014-04-01 | 2019-10-10 |
| Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam PCV10, PCV13 - Pneumococcal Vaccines | Phase 2 / Phase 3 | Completed | Murdoch Childrens Research Institute | 1400 | 2013-09-30 | 2022-09-14 |
| Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life Prevenar13, Synflorix - Otitis Media, Febrile Illness | Phase 4 | Completed | Menzies School of Health Research | 261 | 2013-03-12 | 2020-03-25 |
| Pneumococcal Vaccines Early and in Combination Synflorix, Prevenar13, COMBO - Otitis Media | Phase 4 | Completed | Menzies School of Health Research | 425 | 2011-08-01 | 2018-10-18 |
| Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 576 | 2010-09-27 | 2019-05-29 |
| PCV10 Reactogenicity and Immunogenicity Study - Malindi PCV10 and DTaP, hepatitis A vaccine, DTaP, PCV10 - Pneumococcal Pneumonia | Phase 4 | Unknown | KEMRI-Wellcome Trust Collaborative Research Program | 600 | 2010-01-01 | 2018-02-23 |
| Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children Pneumococcal vaccine GSK1024850A, DTPa - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 360 | 2009-12-08 | 2019-11-29 |
| Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine GSK1024805A, Prevenar, Infanrix hexa - Infections, Streptococcal, Streptococcus Pneumoniae Vaccines | Phase 3 | Completed | GlaxoSmithKline | 524 | 2008-03-03 | 2021-01-27 |
| Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines Synflorix, Tritanrix-HepB, Hiberix - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 756 | 2007-10-22 | 2019-01-14 |
| Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Synflorix, Infanrix hexa, Rotarix - Infections, Rotavirus | Phase 3 | Completed | GlaxoSmithKline | 230 | 2007-09-18 | 2018-06-08 |
| Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule Synflorix, Infanrix Hexa, Havrix - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 163 | 2007-08-22 | 2018-12-19 |
| Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age Synflorix, Infanrix hexa, Rotarix - Infections, Streptococcal, Streptococcus Pneumoniae Vaccines | Phase 3 | Completed | GlaxoSmithKline | 230 | 2007-07-03 | 2020-01-13 |
| Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine. Synflorix, Prevenar, Infanrix hexa - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 1200 | 2006-09-25 | 2019-06-10 |
Showing 20 of 22. Sign in to see all of them.
Streptococcal Infections (8) · Pneumococcal Infections (6) · Pneumonia, Pneumococcal (5) · Haemophilus Infections (2) · Otitis Media (2) · Pneumonia (2) · Cough (1) · Meningitis (1) · Respiratory Syncytial Virus Infections (1) · Respiratory Tract Infections (1) · Rotavirus Infections (1)
GlaxoSmithKline (10) · PATH (3) · Menzies School of Health Research (2) · KEMRI-Wellcome Trust Collaborative Research Program (1) · Murdoch Childrens Research Institute (1) · Nagasaki University (1) · Public Health England (1) · Sungkyunkwan University (1) · University of Oxford (1) · University of Witwatersrand, South Africa (1)
Poland (5) · Finland (3) · United Kingdom (3) · Australia (2) · Kenya (2) · Mexico (2) · The Gambia (2) · Vietnam (2) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1)
Amanda J Leach, PhD (2) · Ed Clarke (1) · Ed Clarke, MB ChB, PhD (1) · Edward K Mulholland, MBBS, FRACP (1) · Elizabeth Coates, PhD (1) · Ju-Young Shin, PhD (1) · Laura Hammitt, MD (1) · Nekoye Otsyula, MD (1) · Shabir A Madhi, MD PhD (1)
PMID 35772449, PMID 38829821, PMID 14998500, PMID 20686433, PMID 24086113, PMID 24465570, PMID 25596202, PMID 26083474, PMID 29884695, PMID 30635252, PMID 30975525, PMID 32448790, PMID 33516293, PMID 33685411, PMID 33745731, PMID 34171233, PMID 36638819, PMID 36785850, PMID 37477875, PMID 37780234, PMID 39417218, PMID 39602629, PMID 41442837, PMID 42202846, PMID 42710524
2015 (1), 2018 (1)